Final outcome of 223Ra-therapy and the role of 18F-fluoride-PET in response evaluation in metastatic castration resistant prostate cancer -a single institution experience.

CONCLUSIONS: From these results we conclude that interim imaging does not help in assessing the final outcome of 223Ra therapy. The survival benefit of 223Ra therapy alone is more than a year in a high risk group of advanced prostate cancer. PMID: 29956640 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29956640?dopt=Abstract

Source: Current Radiopharmaceuticals - July 1, 2018 Category: Radiology Tags: Curr Radiopharm Source Type: research